Page last updated: 2024-12-05

triamterene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Triamterene: A pteridinetriamine compound that inhibits SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

triamterene : Pteridine substituted at positions 2, 4 and 7 with amino groups and at position 6 with a phenyl group. A sodium channel blocker, it is used as a diuretic in the treatment of hypertension and oedema. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5546
CHEMBL ID585
CHEBI ID9671
SCHEMBL ID40707
MeSH IDM0021904

Synonyms (265)

Synonym
BIDD:GT0534
AC-14066
BB 0256885
BRD-K92049597-001-05-9
bdbm6644
pteridine deriv. 11
smr000059118
KBIO1_000433
DIVK1C_000433
EU-0101196
triamterene, >=99%
triazide
SPECTRUM_000508
OPREA1_825704
PRESTWICK_480
cas-396-01-0
NCGC00016016-01
lopac-t-4143
NCGC00016016-02
PRESTWICK3_000034
SMP1_000147
LOPAC0_001196
SPECTRUM5_001034
ademin
pteridine, 2,4,7-triamino-6-phenyl-
taturil
nsc77625
6-phenylpteridine-2,4,7-triamine
noridil
triamterene
nsc639359
396-01-0
trispan
teridin
nci-c56042
noridyl
dyrenium
triamteren
6-phenyl-2,7-triaminopteridine
jatropur
wln: t66 bn dn gn jnj cz ez hr& iz
diurene
pteridine,4,7-triamino-6-phenyl-
triampur
ademine
sk&f 8542
dytac
2,7-triamino-6-phenylpteridine
diren
ditak
pterofen
teriam
skf 8542
tri-span
triteren
nsc-77625
2,7-pteridinetriamine, 6-phenyl-
triamteril
dyren
pterophene
BSPBIO_000127
IDI1_000433
BSPBIO_002924
PRESTWICK2_000034
NCGC00023458-03
AB00052116
trizid
kalspare
ccris 5872
triamterena [inn-spanish]
uretren
nci c56042
nephral
2,4,7-triamino-6-phenylpteridine
triamizide
hsdb 3405
sali-puren
dyberzide
dinazide
amteren
diuteren
isobar
masuharmin
esiteren
2,4,7-triamino-6-fenilpteridina [italian]
fluss 40
ademin(e)
urocaudal
apo-triazide
triamthiazid
reviten
nsc 77625
2,4,7-pteridinetriamine, 6-phenyl-
renezide
nsc 639359
hidiurese
diucelpin
hypertorr
6-phenyl-2,4,7-triaminopteridine
thiazid wolff
brn 0266723
turfa
dytenzide
jenateren
anjal
hydrene
einecs 206-904-3
6-phenyl-2,4,7-pteridinetriamine
triamterenum [inn-latin]
triurene
diutensat
ai3-60017
tricilone
diarol
dazid
STK300348
DB00384
D00386
dyrenium (tn)
triamterene (jp17/usp/inn)
NCGC00023458-05
NCGC00023458-07
MLS000069431
KBIO2_000988
KBIO2_003556
KBIO2_006124
KBIOGR_000831
KBIO3_002144
KBIOSS_000988
NCIOPEN2_004741
SPBIO_000876
PRESTWICK0_000034
SPBIO_002048
PRESTWICK1_000034
SPECTRUM3_001372
SPECTRUM4_000366
SPECTRUM2_000938
NINDS_000433
SPECTRUM1500589
BPBIO1_000141
NCGC00023458-04
NCGC00016016-03
NCGC00023458-06
NCGC00016016-07
HMS2092O17
T 4143 ,
NCGC00016016-12
sk&f-8542
sk-8542
CHEMBL585
nsc-639359
HMS501F15
T1288
HMS1568G09
NCGC00016016-10
AKOS003790819
HMS3259C08
HMS3263P13
HMS2095G09
triamterenum
triamterene [usan:usp:inn:ban:jan]
2,4,7-triamino-6-fenilpteridina
ws821z52lq ,
5-26-17-00447 (beilstein handbook reference)
triamterena
unii-ws821z52lq
dtxsid6021373 ,
tox21_302833
NCGC00256495-01
dtxcid001373
tox21_202021
NCGC00259570-01
A824641
nsc-757367
pharmakon1600-01500589
nsc757367
tox21_110283
HMS2232B04
S4080
CCG-40090
NCGC00016016-11
NCGC00016016-09
NCGC00016016-13
NCGC00016016-14
NCGC00016016-06
NCGC00016016-16
NCGC00016016-08
NCGC00016016-15
NCGC00016016-04
NCGC00016016-05
LP01196
triamterene [orange book]
triamterene [hsdb]
maxzide component triamterene
triamterene component of maxzide
triamterene [who-dd]
triamterene [vandf]
triamterene [usp-rs]
triamterene [mart.]
triamterene [jan]
triamterene [mi]
triamterene [usan]
dyazide component triamterene
triamterene component of dyazide
triamterene [ep monograph]
triamterene [inn]
triamterene [iarc]
triamterene [usp monograph]
triamterene [usp impurity]
gtpl4329
HMS3371D10
HY-B0575
NC00544
SCHEMBL40707
NCGC00016016-18
tox21_110283_1
NCGC00261881-01
tox21_501196
FNYLWPVRPXGIIP-UHFFFAOYSA-N
dyazide (salt/mix)
AB00052116_13
AB00052116_14
mfcd00006708
skf8542
sr-01000002968
SR-01000002968-2
triamterene, united states pharmacopeia (usp) reference standard
Z275128596
HMS3652E10
triamterene, pharmaceutical secondary standard; certified reference material
triamterene, european pharmacopoeia (ep) reference standard
triamterene 1.0 mg/ml in dimethyl sulfoxide
SR-01000002968-4
SR-01000002968-6
CHEBI:9671 ,
SBI-0051163.P003
HMS3712G09
triamterene, british pharmacopoeia (bp) reference standard
SW196688-3
Q221520
AS-12471
BCP28855
BRD-K92049597-001-10-9
SDCCGSBI-0051163.P004
NCGC00016016-29
D95706
NCGC00016016-28
EN300-119540
c03db02
triamterenum (inn-latin)
triamterene (iarc)
triamterena (inn-spanish)
triamterene (usan:usp:inn:ban:jan)
triamterene (usp impurity)
triamterenum (latin)
triamterene (usp monograph)
triamtereno
triamterene (mart.)
triamterene (usp-rs)
triamterene capsules
triamterene (ep monograph)
triamterene (standard)
CS-0695001
HY-B0575R
2,4-diamino-6-phenyl-7-pteridinylamine

Research Excerpts

Overview

Triamterene is a strong absorber in the ultraviolet region and has an unusual UV spectrum, which simplifies the identification and quantitation of this substance by high-performance liquid chromatography. It is used in combination with other more potent diuretics in the treatment of hypertension.

ExcerptReferenceRelevance
"Triamterene is a strong absorber in the ultraviolet region and has an unusual UV spectrum, which simplifies the identification and quantitation of this substance by high-performance liquid chromatography."( The identification and quantitation of triamterene in blood and urine from a fatal aircraft accident victim.
Canfield, DV; Hordinsky, J; White, V,
)
1.12
"Triamterene is a pteridine used therapeutically as a diuretic. "( Variations in the fate of triameterene.
Dayton, PG; Pruitt, AW; Winkel, JS, 1977
)
1.7
"Triamterene (TA) is a mild 'potassium-sparing' diuretic usually employed in combination with other more potent diuretics in the treatment of hypertension. "( Triamterene and the kidney.
Gehr, TW; Sica, DA, 1989
)
3.16
"Triamterene is a potassium-sparing diuretic used in patients with cirrhosis for the treatment of ascites. "( Kinetics and dynamics of triamterene at steady-state in patients with cirrhosis.
Dao, MT; Villeneuve, JP, 1988
)
2.02
"Triamterene therapy is an unusual cause of nephrolithiasis and, when this agent is found in a stone, generally it is deposited in minor amounts. "( Triamterene calculus.
Dickstein, ES; Loeser, WD, 1985
)
3.15

Effects

Triamterene has to be administered twice a day while amiloride and spironolactone are effective for 24 hours. The drug has no specific effect on the membrane-bound ATPase.

ExcerptReferenceRelevance
"Triamterene has a similar effect, although with a lower affinity; the available studies do not allow to determine if an inhibitory effect of triamterene on the Na-K-ATPase plays an additional role in its diuretic action."( Potassium-sparing diuretics.
Giebisch, G; Horisberger, JD, 1987
)
0.99
"Triamterene has been reported to show low bioavailability after oral administration, with wide intersubject variation."( Triamterene-beta-cyclodextrin systems: preparation, characterization and in vivo evaluation.
Mukne, AP; Nagarsenker, MS, 2004
)
2.49
"Triamterene has to be administered twice a day while amiloride and spironolactone are effective for 24 hours."( [Pharmacology of potassium-sparing diuretics].
Dominiak, P, 1997
)
1.02
"Triamterene has no specific effect on the membrane-bound ATPase."( [Inhibition of the exchange of Na+ for K+ and and H+ by triamterene (in epithelia)(author's transl)].
Albiez, G; Knauf, H; Lübcke, R; Wais, U, 1976
)
1.22
"Triamterene has been previously reported to cause acute reversible renal failure, but to our knowledge, this is the first case of irreversible renal failure due to intratubular obstruction by triamterene crystal deposition."( Irreversible renal failure associated with triamterene.
Dufresne, LR; Dumont, A; Duran, MA; Jobin, J; Morin, C; Roy, LF; Villeneuve, JP, 1991
)
1.27
"Triamterene has a similar effect, although with a lower affinity; the available studies do not allow to determine if an inhibitory effect of triamterene on the Na-K-ATPase plays an additional role in its diuretic action."( Potassium-sparing diuretics.
Giebisch, G; Horisberger, JD, 1987
)
0.99

Actions

Triamterene is frequently used in combination with hydrochlorothiazide (HCTZ) to treat patients with hypertension.

ExcerptReferenceRelevance
"Triamterene was found to inhibit HDACs. "( Repurposing of triamterene as a histone deacetylase inhibitor to overcome cisplatin resistance in lung cancer treatment.
Cheung, KM; Cho, WCS; To, KKW, 2023
)
2.71
"Triamterene, because of its potassium-sparing properties, is frequently used in combination with hydrochlorothiazide (HCTZ) to treat patients with hypertension. "( Triamterene Enhances the Blood Pressure Lowering Effect of Hydrochlorothiazide in Patients with Hypertension.
Decker, BS; Eckert, GJ; Erdel, BL; He, Z; Hellman, RN; Murray, MD; Oates, JA; Pratt, JH; Tu, W, 2016
)
3.32
"The triamterene induced increase of plasma potassium concentration may contribute to the antitoxic effect, however, the effect persisted after the decrease of plasma potassium concentration (by addition of NaHCO3) to pretreatment values."( [The antitoxic action of triamterene in cardiac glycoside poisoning].
Güttler, K; Jenke, J; Klaus, W, 1986
)
1.06

Treatment

Treatment with triamterene (100 mg/d; n = 10) over a period of 3 weeks led to an increase of serum potassium (from 4.1 +/- 0.65 to 4.7 +/-0.51 mmol/l) and of total body potassium (by 110 mmol). . Pretreatment with Triam terene significantly reduces the ouabain toxicity indicated by an increase in arrhythmia.

ExcerptReferenceRelevance
"Treatment with triamterene (100 mg/d; n = 10) over a period of 3 weeks led to an increase of serum potassium (from 4.1 +/- 0.65 to 4.7 +/- 0.51 mmol/l) and of total body potassium (by 110 mmol)."( [Serum and total body potassium during treatment with chlortalidone and hydrochlorothiazide. Influence of triamterene (author's transl)].
Kaltenbach, M; Kober, G; Schäfer, GE; Werner, E, 1977
)
0.81
"Pretreatment with triamterene (5 mg/kg and 10 mg/kg) significantly reduces the ouabain toxicity indicated by an increase of the dose producing arrhythmia (from 61 +/- 14 to 121 +/- 17 and 178 +/- 22 micrograms/kg, resp.) and lethality (from 114 +/- 18 to 236 +/- 5 and 329 +/- 11 micrograms/kg, resp.)."( [The antitoxic action of triamterene in cardiac glycoside poisoning].
Güttler, K; Jenke, J; Klaus, W, 1986
)
0.9

Toxicity

ExcerptReferenceRelevance
" Triamterene had no adverse effects on mating or fertility and did not induce dominant lethal mutations in the germ cells of male mice when given for 5 days at 5-100 mg/kg/day."( Lack of in vivo mutagenicity and testicular toxicity of triamterene in mice.
Brown, T; Guerriero, FJ; Manson, JM; San Sebastian, J, 1986
)
1.43
" After single intravenous application in mice, derivatives with a basic side-chain were much more toxic than compounds with an acidic side-chain."( Investigations on the acute toxicity of acidic and basic triamterene derivatives.
Mutschler, E; Netzer, T; Priewer, H; Ullrich, F; Vollmer, G; Wolf, E, 1995
)
0.54

Pharmacokinetics

Triamterene was increased in the elderly patients compared with the data of young healthy volunteers. The interaction resulted in a small attenuation of the pharmacodynamic response to triam terene.

ExcerptReferenceRelevance
" Mean peak concentration of triamterene was increased in the elderly patients compared with the data of young healthy volunteers."( Pharmacokinetics of triamterene in geriatric patients--influence of piretanide and hydrochlorothiazide.
Jung, R; Mühlberg, W; Mutschler, E; Platt, D; Spahn, H, 1989
)
0.89
" The interaction resulted in a small attenuation of the pharmacodynamic response to triamterene."( Pharmacokinetic drug interactions between triamterene and ranitidine in humans: alterations in renal and hepatic clearances and gastrointestinal absorption.
Bochner, F; Muirhead, M; Somogyi, A, 1988
)
0.76
" Triamterin pharmacokinetic studies may be used for the screening of hypertensive patients as potential candidates for triampur treatment."( [Relation between the hypotensive effect of triampur and its pharmacokinetics in patients with hypertension].
Kuznetsov, GP; Lebedev, PA, 1986
)
0.27
"The pharmacokinetic profiles of triamterene and hydroxytriamterene sulfuric acid ester, the major metabolite of triamterene, were studied in six normal male volunteers using a newly developed specific HPLC analytical method."( Pharmacokinetics of triamterene and its metabolite in man.
Benet, LZ; Hasegawa, J; Lin, ET; Sörgel, F; Williams, RL, 1982
)
0.87
" A pharmacokinetic characteristics of new drug adalate SL with two-step liberation of nifedipine."( [The pharmacokinetics of different drug forms of nifedipine when used singly and in a course as monotherapy and in combination with Cordanum and triampur preparations in patients with arterial hypertension].
Ignat'ev, VG; Kukes, VG; Pavlov, SS; Starodubtsev, AK,
)
0.13
" Therefore, the aim of this study was to examine the dose linearity of TA and the pharmacokinetic and pharmacodynamic interaction of triamterene and hydrochlorothiazide."( Pharmacokinetics and pharmacodynamics of triamterene and hydrochlorothiazide and their combination in healthy volunteers.
Knauf, H; Möhrke, W; Mutschler, E, 1997
)
0.77
" Furthermore, the pharmacodynamic action of diuretics was not significantly altered in the elderly."( Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged.
Bischoff, I; Block, S; Fliser, D; Hanses, A; Joest, M; Mutschler, E; Ritz, E, 1999
)
0.3
"The object of the work was comparative study of the special features of the pharmacodynamic and pharmacokinetic properties of the diuretics furosemide and furesis in an ambulant regimen with the subject lying in an antiorthostatic position."( [The pharmacodynamic and pharmacokinetic characteristics of furosemide and furesis].
Goncharov, IB; Kodratenko, SN; Kovachevich, IV; Noskov, VB; Sokolova, EV; Starodubtsev, AK,
)
0.13
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" The method was used to determine the urinary excretion profile and to calculate different urinary pharmacokinetic parameters following oral dose of their combination compared with single oral doses of each drug and hence comparing their bioavailability."( Bioavailability study of triamterene and xipamide using urinary pharmacokinetic data following single oral dose of each drug or their combination.
Barary, MA; El-Kimary, EI; Hassan, EM; Maher, HM; Youssef, RM, 2012
)
0.68

Compound-Compound Interactions

The antihypertensive effects and impact of hydrochlorothiazide (HCT) alone or in combination with triamterene or amiloride on the hemodynamics of 79 patients with Stage II hypertension. The optimal daily dose and dose regimen of a new drug combination (Pertenso) was tested in 14 hypertensive outpatients.

ExcerptReferenceRelevance
"A comparative study was undertaken to examine antihypertensive effects and impact of hydrochlorothiazide (HCT) alone or in combination with triamterene or amiloride on the hemodynamics of 79 patients with Stage II hypertension."( [Comparative study of the hypotensive action of monotherapy using hydrochlorothiazide and its combination with triamterene and amiloride and their effect on hemodynamics at rest and during exercise therapy].
Glezer, GA; Levinzon, AM; Lipko, DS, 1990
)
0.69
"In a study of cross-over randomized design in 12 healthy volunteers we compared the effect on magnesium excretion after administration of single oral doses of frusemide 40 mg (F) and of frusemide 40 mg in combination with a single dose of triamterene 50 mg (F+T)."( Absence of magnesium sparing effect of a single dose of triamterene in combination with frusemide in healthy male adults.
Gribnau, FW; Smits, P; van Meyel, JJ, 1990
)
0.71
" It is concluded that in a clinical daily practice of a hypertension clinic low doses of spironolactone or of thiazides combined with potassium-sparing agents reduced BP without alteration in lipid or carbohydrate metabolism on long-term follow-up."( Long-term metabolic effects of spironolactone and thiazides combined with potassium-sparing agents for treatment of essential hypertension.
Charru, A; Chatellier, G; Corvol, P; Degoulet, P; Jeunemaitre, X; Julien, J; Ménard, J; Plouin, PF, 1988
)
0.27
"The antihypertensive and biochemical effects of 25 mg hydrochlorothiazide alone or 50 mg hydrochlorothiazide alone or in combination with triamterene (either 37."( Antihypertensive and biochemical effects of different doses of hydrochlorothiazide alone or in combination with triamterene.
Eisalo, A; Gordin, A; Kohvakka, A; Salo, H, 1986
)
0.68
"The optimal daily dose and dose regimen of a new drug combination (Pertenso), consisting of 10 mg bemetizide, 20 mg triamterene, 20 mg dihydralazine and 20 mg bupranolol were tested in 14 hypertensive outpatients (WHO I to III) in a single blind crossover trial."( [Treatment of hypertension with a drug combination, consisting of bemetizide, triamterene, dihydralazine and bupranolol (author's transl)].
Brandstetter, G; Gasser, RW; Skrabal, F, 1982
)
0.7
"This study was performed to compare the effect of one month's treatment with hydrochlorothiazide (25 mg) in combination with either amiloride (2."( A study of plasma sodium levels in elderly people taking amiloride or triamterene in combination with hydrochlorothiazide.
Bielawska, CA; Fidler, HM; Goldman, J; Hoffbrand, BI; Rai, GS, 1993
)
0.52
" Good response was noted in corinfar-retard combination with Cordanum in patients with moderate hemodynamic changes, hypertonicity of sympathoadrenal system, tachycardia."( [The clinical efficacy of Korinfar-retard in combination with Cordanum, triampur and Capoten in patients with arterial hypertension].
Chil'tsov, VV; Ignat'ev, VG; Kukes, VG; Pavlov, SS; Pavlova, LI; Privalov, AN; Rumiantsev, AS, 1996
)
0.29

Bioavailability

The purpose of this research was to improve the solubility and therefore dissolution and bioavailability of triamterene, a poorly water soluble diuretic, by complexation with beta-cyclodextrin.

ExcerptReferenceRelevance
" Relative bioavailability of the FR and SR formulations were 82 and 41%, respectively, compared to the commercial tablet."( In vitro/in vivo evaluation of hydrochlorothiazide in experimental hydrochlorothiazide/triamterene combination tablets in beagle dogs.
Lipps, D; Ritschel, WA; Sakr, A; Turkoglu, M; Warner, A, 1991
)
0.5
" The second study (II) assessed the bioavailability of the new product given as a single tablet on two occasions separated by an interval of 12 h compared to the full-strength product given as a single dose."( Absorption and disposition of a new low-dose combination formulation of hydrochlorothiazide and triamterene.
Benet, LZ; Blume, CD; Liang-Gee, W; Lin, ET; Williams, RL, 1990
)
0.5
"5 mg of triamterene) to one capsule of Dyazide (25 mg of hydrochlorothiazide and 50 mg of triamterene) to determine if the difference in bioavailability would be reflected in differences in blood pressure control and metabolic changes."( A comparison of the anti-hypertensive effectiveness of two triameterene/hydrochlorothiazide combinations: Maxzide versus Dyazide.
Casner, PR; Dillon, KR, 1990
)
0.71
"The clinical efficacy, safety, and bioavailability of a generic triamterene-hydrochlorothiazide product were compared with those of Dyazide."( Comparative efficacy and bioequivalence of a brand-name and a generic triamterene-hydrochlorothiazide combination product.
Cane, RC; Costello, K; Goodwin, P; Perkal, M; Sharoky, M; Tabatznik, B, 1989
)
0.75
" T bioavailability from capsules was poorer and more variable than that from a suspension."( Oral triamterene disposition.
Hasegawa, J; Lin, ET; Sörgel, F; Williams, RL, 1985
)
0.78
"In a pharmacokinetic study on 18 healthy male volunteers the bioavailability and elimination kinetics of furosemide-retard and the combination furosemide-retard/triamterene were investigated and compared with the non-retarded form and another retard form of furosemide."( Bioavailability and elimination kinetics of the combination furosemide-retard/triamterene.
Knoell, HE; Loew, D; Schuster, O,
)
0.56
" This reduced bioavailability may reduce its effectiveness in hypertensive patients who change from optimally bioavailable hydrochlorothiazide tablets to Dyazide capsules in an effort to correct hypokalemia."( A new antihypertensive agent: Maxzide (75 mg triamterene/50 mg hydrochlorothiazide).
Blume, CD; Williams, RL, 1984
)
0.53
" Furthermore, because of the bioavailability of the pharmaceutical formulation, the dose the patient "takes" may not be the one that he or she actually gets."( Effect of bioavailability on dose-response relationships.
Goldman, P, 1984
)
0.27
" The clinical consequences of the limited bioavailability of the active ingredients of Dyazide are discussed."( Bioequivalence study of a new tablet formulation of triamterene and hydrochlorothiazide.
Benet, LZ; Blume, CD; Lin, ET; Upton, RA; Williams, RL, 1984
)
0.52
" In contradiction to a recent publication, no interaction between the drugs affecting the bioavailability or renal clearance of either could be demonstrated."( Absence of a significant pharmacokinetic interaction between hydrochlorothiazide and triamterene when coadministered.
Benet, LZ; Blume, CD; Gee, WL; Lin, ET; Upton, RA; Williams, RL, 1984
)
0.49
" The bioavailability of TA was 52%, corresponding to absorption of 83%."( Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability.
Gilfrich, HJ; Kremer, G; Möhrke, W; Mutschler, E; Völger, KD, 1983
)
0.59
" Comparing these data with results after oral application of TA the bioavailability of TA was 52% and the extent of absorption 83%."( [Pharmacokinetics of triamterene in healthy subjects and patients with liver and kidney function disorders].
Gilfrich, HJ; Knauf, H; Möhrke, W; Mutschler, E; Völger, KD, 1983
)
0.58
" A pilot bioavailability study was carried out in four normal healthy male volunteers."( Preliminary observations on dissolution and bioavailability of triamterene-hydrochlorothiazide combination products.
Cabana, BE; Knapp, G; Lin, J; Prasad, VK; Shah, VP; Walker, MA,
)
0.37
" Comparing these data with results after oral application of TA the bioavailability of TA was 52% and the extent of absorption 83%."( Pharmacokinetics of triamterene.
Gilfrich, HJ; Knauf, H; Möhrke, W; Mutschler, E; Völger, KD, 1983
)
0.59
"In a study on the bioavailability of triamterene and hydrochlorothiazide from 3 diuretics, preparation A (25 mg hydrochlorothiazide), preparation B (50 mg triamterene) and preparation C (combination of hydrochlorothiazide and triamterene), the data for tmax, Cmax, AUC and the cumulative urine excretion were determined in 7 healthy volunteers."( [On the bioavailability of hydrochlorothiazide and triamterene from commercial drugs (author's transl)].
Knauf, H; Möhrke, W; Mutschler, E; Völger, KD, 1980
)
0.79
"The oral bioavailability of triamterene in rats was investigated after its administration as a suspension in lipid and aqueous vehicles in addition to lactic acid solution."( Effect of various vehicles and vehicle volumes on oral absorption of triamterene in rats.
Gilford, P; Patton, TF, 1981
)
0.79
" To increase the dissolution rate and subsequent oral bioavailability of this drug, it has been formulated as solid dispersion."( The application of solid dispersion technique with D-mannitol to the improvement in oral absorption of triamterene.
Arias, MJ; Gines, JM; Moyano, JR; Rabasco, AM, 1994
)
0.5
"The applicability of the solid dispersion technique as a method for enhancing the GI absorption of a drug has been explored in order to procure better dissolution characteristics and better bioavailability for triamterene."( Dissolution properties and in vivo behaviour of triamterene in solid dispersions with polyethylene glycols.
Arias, MJ; Ginés, JM; Moyano, JR; Rabasco, AM, 1996
)
0.74
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" Papp of IDM was greater than that of TAT, indicating that the order corresponded with that of in vivo bioavailability after oral administration of their PEG 600 solutions."( Evaluation of absorbability of poorly water-soluble drugs: validity of the use of additives.
Hayashi, M; Sudo, R; Takahashi, M; Watanabe, E, 2000
)
0.31
" The parameter used to quantify absorption was the absorption rate constant, determined in situ by means of a loop perfusion technique, performed in colon and in whole small intestine of rat at three pHs (5."( Kinetic modeling of triamterene intestinal absorption and its inhibition by folic acid and methotrexate.
Bermejo, M; García-Valcárcel, I; Garrigues, TM; Merino, V; Montalar, M; Nalda-Molina, R; Rodríguez-Ibáñez, M, 2003
)
0.64
"The purpose of this research was to improve the solubility and therefore dissolution and bioavailability of triamterene, a poorly water soluble diuretic, by complexation with beta-cyclodextrin."( Triamterene-beta-cyclodextrin systems: preparation, characterization and in vivo evaluation.
Mukne, AP; Nagarsenker, MS, 2004
)
1.98
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
" Statistical comparison showed that the test and reference products were bioequivalent in terms of both the rate and extent of bioavailability of both active ingredients."( Bioequivalence evaluation of a triamterene-hydrochlorothiazide generic product: a new bioequivalence index for fixed-dose combinations.
Azimi, K; Hamidi, M; Shahbazi, MA, 2011
)
0.66
" This study is designed to evaluate a CB[7]-based pharmaceutical formulation to improve solubility and bioavailability of triamterene (a mild potassium-sparing diuretic)."( The delivery of triamterene by cucurbit[7]uril: synthesis, structures and pharmacokinetics study.
Chen, JM; Jiang, L; Lu, TB; Ma, WJ; Yao, J, 2013
)
0.94
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Sensitive, simple and specific spectrophotometric and spectrofluorimetric methods were developed for the determination of triamterene in bulk powder and pharmaceutical dosage form. Their effects on electrolyte excretion were tested with dose-response curves in rats.

ExcerptRelevanceReference
" Thus, this long-term study provides additional evidence that diuretics have a flat dose-response curve with respect to their antihypertensive efficacy, whereas lower doses might cause less pronounced activation of counter-regulatory systems."( Long-term diuretic therapy: effects of dose reduction on antihypertensive efficacy and counterregulatory systems.
Ripka, O; Weisser, B, 1992
)
0.28
" In the same model a dose-response curve was performed for RPH 3036."( Effects of a new pteridine derivative on urinary sodium, potassium and magnesium excretion in conscious saline-loaded rats.
Majewski, M; Mutschler, E; Netzer, T; Priewer, H; Ullrich, F, 1992
)
0.28
"Behavioral performances of six baboons were tested during chronic oral dosing with diuretic (hydrochlorothiazide/triamterene), a calcium channel blocker (verapamil), and a combination of the two drugs."( Behavioral effects of chronic, orally administered diuretic and verapamil in baboons.
Hienz, RD; Turkkan, JS, 1991
)
0.49
"We studied the dose-response relationship for hydrochlorothiazide + triameterene and verapamil, comparing monotherapy with combined treatment in 216 hypertensive patients over 3 weeks of active treatment following a 2-week washout period with placebo."( Dose-response curves in antihypertensive combination therapy: results of a controlled clinical trial.
Bluemner, E; Letzel, H, 1990
)
0.28
"On isolated electrically stimulated left and spontaneously beating right guinea-pig atria the interaction between PDE-inhibitors and the positive inotropic and chronotropic action of orciprenaline, forskolin and histamine in dose-response curve was examined."( Interaction of phosphodiesterase inhibitors triamterene, papaverine, theophylline, IBMX and amrinone with other positive inotropic acting substances on isolated guinea-pig atria.
Greeff, K; Schmitt, M, 1987
)
0.53
" In elderly patients reduction or correction of the dosage seems to be necessary for all three diuretics investigated in our studies."( Pharmacokinetics of diuretics in geriatric patients.
Mühlberg, W,
)
0.13
" In comparative studies, the piretanide dose-response curve was found to be parallel to that of frusemide over the dose range studied."( Acute and long-term renal and metabolic effects of piretanide in congestive cardiac failure.
Lant, AF; McNabb, WR; Noormohamed, FH, 1988
)
0.27
" Multiple blood and urine samples were collected throughout a dosing interval after chronic administration of triamterene alone, ranitidine alone or the two in combination."( Pharmacokinetic drug interactions between triamterene and ranitidine in humans: alterations in renal and hepatic clearances and gastrointestinal absorption.
Bochner, F; Muirhead, M; Somogyi, A, 1988
)
0.75
" In the controls the average plasma concentration of triamterene during a dosage interval was 45 +/- 8 ng/ml and that of hydroxy-triamterene sulfate, an active metabolite of triamterene, was 967 +/- 177 ng/ml."( Kinetics and dynamics of triamterene at steady-state in patients with cirrhosis.
Dao, MT; Villeneuve, JP, 1988
)
0.83
" Eumagnesaemia and eupotassaemia were preserved at all dosage of the piretanide monosubstance."( Lack of effect of piretanide (a potassium-stable diuretic) on serum magnesium.
de Looze, S; Irmisch, R; Rangoonwala, B; Verho, M, 1987
)
0.27
" Their effects on electrolyte excretion were tested with dose-response curves in rats: a dissociation of ED50 values of Na+ excretion from those of K+ retention was found; while the ED50 values of natriuresis were structure independent, the ED50 values for potassium retention depended highly on the charge of the side chain of triamterene derivatives."( Dissociation of the natriuretic and antikaliuretic properties of triamterene derivatives by dose-response experiments.
Knauf, H; Kraft, H; Mutschler, E; Priewer, H; Wolf, E, 1987
)
0.68
" In examining the effects of diuretics on Mg and K metabolism, the following factors should be taken into account: site of action and duration of action of diuretics, duration of treatment and dosage used, concurrent drug therapy, underlying disease conditions and dietary intake of Mg."( Magnesium and potassium-sparing diuretics.
Ryan, MP, 1986
)
0.27
"In this study we compared the absorption and disposition of two commonly used combination formulations of hydrochlorothiazide and triamterene (Dyazide and Maxzide) in 48 patients with essential hypertension after dosing with each formulation to steady state."( Absorption and disposition of two combination formulations of hydrochlorothiazide and triamterene: influence of age and renal function.
Benet, LZ; Blume, C; Clark, TS; Lin, E; Thornhill, MD; Upton, RA; Williams, RL, 1986
)
0.7
" Blood and urine samples were collected frequently for 24 hours after dosing with triamterene alone (100 mg/day) for 4 days and concomitant cimetidine (400 mg twice daily) for an additional 4 days."( Effect of cimetidine on renal and hepatic drug elimination: studies with triamterene.
Bochner, F; Muirhead, MR; Rolan, PE; Somogyi, AA, 1986
)
0.73
" The combination of furosemide and triamterene brought about a 'softer' diuresis, no hypokalaemia and the advantage of dosage as only one tablet, thus eliminating the need for taking two separate drugs."( Comparison of the efficacy of furosemide with two furosemide-triamterene combinations in the treatment of cardiac insufficiency.
Ojasalo, T; Saarimaa, H, 1985
)
0.79
" Triamterene seemed ineffective in the dosage used (50 mg twice daily)."( Potassium-sparing agents during diuretic therapy in hypertension.
Brien, TG; Canning, BS; Donohoe, JF; Healy, JJ; McKenna, TJ; Muldowney, FP, 1971
)
1.16
" The ratios of the apparent off-rate and on-rate constants (the microscopic inhibition constants) thus obtained for triamterene, triaminopyrimidine (TAP), 5,6-diCl-amiloride, 5H-amiloride and amiloride itself are found to be in the mean about sevenfold smaller than the corresponding inhibition constants obtained from macroscopic dose-response curves."( Competitive blocking of epithelial sodium channels by organic cations: the relationship between macroscopic and microscopic inhibition constants.
Li, JH; Lindemann, B, 1983
)
0.48
" A dose-response relationship has been established for the effect of amiloride in reducing fractional excretion of magnesium and potassium during frusemide diuresis in rats."( Effects of diuretics on the renal handling of magnesium.
Counihan, TB; Devane, J; Ryan, MF; Ryan, MP, 1984
)
0.27
"Twenty patients with mild to moderate hypertension participated in a single-blind crossover comparison of treatment with 25 mg hydrochlorothiazide plus 50 mg triamterene and 50 mg hydrochlorothiazide plus 5 mg amiloride in once-daily dosage regimens."( Hydrochlorothiazide in combination with potassium-sparing agents in the treatment of hypertension.
Dean, S; Spencer-Mills, L, 1984
)
0.46
" The dosage range that is likely to cause the hypotensive effect without the potassium loss has been called the "therapeutic window."( Effect of bioavailability on dose-response relationships.
Goldman, P, 1984
)
0.27
" A well-formulated hydrochlorothiazide-triamterene combination tablet promotes plasma concentrations and urinary excretion of hydrochlorothiazide, triamterene, and hydroxytriamterene sulfate which are virtually identical to those seen after either a combination liquid dosage form or simple liquid forms containing only one of the two drugs."( Absence of a significant pharmacokinetic interaction between hydrochlorothiazide and triamterene when coadministered.
Benet, LZ; Blume, CD; Gee, WL; Lin, ET; Upton, RA; Williams, RL, 1984
)
0.76
" The bioavailability of different dosage forms was correlated with in vitro-tests."( [Pharmacokinetics of triamterene in healthy subjects and patients with liver and kidney function disorders].
Gilfrich, HJ; Knauf, H; Möhrke, W; Mutschler, E; Völger, KD, 1983
)
0.58
" The bioavailability of different dosage forms was correlated with in vitro tests."( Pharmacokinetics of triamterene.
Gilfrich, HJ; Knauf, H; Möhrke, W; Mutschler, E; Völger, KD, 1983
)
0.59
" However, when the vehicle volume was reduced to a realistic dosage form volume for the rat, peanut oil and aqueous suspensions were indistinguishable from each other with respect to peak height, peak time, and overall bioavailability."( Effect of various vehicles and vehicle volumes on oral absorption of triamterene in rats.
Gilford, P; Patton, TF, 1981
)
0.5
" It allows instant evaluation of a patient's dosing record, at the patient's return to the practice."( Patterns of drug compliance with medications to be taken once and twice daily assessed by continuous electronic monitoring in primary care.
Kruse, W; Rampmaier, J; Ullrich, G; Weber, E, 1994
)
0.29
" After the first 4 weeks, the patients who responded to the initial dosage (a reduction in systolic blood pressure of at least 15 mm Hg) or whose blood pressure was controlled on the dosage (systolic blood pressure < 140 mm Hg) continued to take the low dose."( Felodipine extended release versus conventional diuretic therapy for the treatment of systolic hypertension in elderly patients. The National Trial Group.
McClennen, W; Wilson, T, 1998
)
0.3
" For drugs with a narrow therapeutic window, indirect estimates of GFR appear to be an unreliable means for calculating correct dosage in the elderly."( Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged.
Bischoff, I; Block, S; Fliser, D; Hanses, A; Joest, M; Mutschler, E; Ritz, E, 1999
)
0.3
" Stone prevention is based on drug withdrawal or change in dosage with additional measures including an increase of diuresis and, if necessary, changes in the urine pH."( [Drug-induced urinary calculi in 1999].
Daudon, M, 1999
)
0.3
" Chlorthiazide's toxic dose for 50% of animals tested (TD50) could not be achieved even with dosing as high as 1,500 mg/kg for furosemide; TD50 was 549 mg/kg."( Are certain diuretics also anticonvulsants?
Annegers, JF; Cascino, G; Hauser, WA; Hesdorffer, DC; Stables, JP, 2001
)
0.31
" The photoreactivity of the drugs was exploited to develop an HPLC method involving a post-column on-line photochemical derivatization useful to confirm the analyte identity in a commercial dosage form (tablets)."( Photostability studies on the furosemide-triamterene drug association.
Andrisano, V; Ballardini, R; Cavrini, V; Fiori, J, 2003
)
0.58
" The daily dosage of triamterene ranged from 50 to 250 mg."( TREATMENT OF CONGESTIVE HEART FAILURE WITH TRIAMTERENE.
FRIEDMAN, R; SCHUCHER, R; WENER, J, 1965
)
0.82
" Urine samples were collected 24 hours before dosing and between 0 - 1, 1 - 2, 2 - 3, 3 - 4, 4 - 6, 6 - 8, 8 - 12, and 12 - 24 hours post-dosing."( Attenuation of the kaluretic properties of furosemide by triamterene (Dyrenium) in healthy volunteers.
Levinson, B; Shenouda, M; Stypinski, D, 2005
)
0.57
"A novel, simple and robust high-performance liquid chromatography (HPLC) method was developed and validated for simultaneous determination of xipamide (XIP), triamterene (TRI) and hydrochlorothiazide (HCT) in their bulk powders and dosage forms."( High performance liquid chromatography for simultaneous determination of xipamide, triamterene and hydrochlorothiazide in bulk drug samples and dosage forms.
Abd El-Hay, SS; Gouda, AA; Hashem, H, 2016
)
0.86
"Sensitive, simple and specific spectrophotometric and spectrofluorimetric methods were developed for the determination of triamterene in bulk powder and pharmaceutical dosage form."( Validated spectroscopic methods for the estimation of triamterene in bulk powder and capsule form via derivatization reactions.
Fathy, ME; Fouad, MM; Ibrahim, FA; Mahmoud, ES; Rashed, NS, 2018
)
0.94
"To establish and validate rapid and accurate UPLC and TLC densitometric methods for determination of Xipamide and Triamterene in pure and dosage forms."( Ultra-Performance Liquid Chromatographic and Densitometric Methods for Sensitive Determination of Xipamide and Triamterene in Pure and Pharmaceutical Dosage Forms.
Abd El Ghany, MF; Badawey, AM; El Fiky, HA; Fares, NV, 2022
)
1.14
" Both proposed methods were sensitive, selective, and effectively applied to pure and dosage forms (Epitens®)."( Ultra-Performance Liquid Chromatographic and Densitometric Methods for Sensitive Determination of Xipamide and Triamterene in Pure and Pharmaceutical Dosage Forms.
Abd El Ghany, MF; Badawey, AM; El Fiky, HA; Fares, NV, 2022
)
0.93
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
diureticAn agent that promotes the excretion of urine through its effects on kidney function.
sodium channel blockerAn agent that inhibits sodium influx through cell membranes.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
pteridines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Triamterene Action Pathway319

Protein Targets (139)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, PAPAINCarica papaya (papaya)Potency22.38720.300012.534831.6228AID2161
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency24.03530.003245.467312,589.2998AID1705; AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency12.58930.004023.8416100.0000AID485290
Chain A, HADH2 proteinHomo sapiens (human)Potency3.83760.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency3.83760.025120.237639.8107AID886; AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency6.66660.177814.390939.8107AID2147
Chain A, Ferritin light chainEquus caballus (horse)Potency28.83745.623417.292931.6228AID2323; AID485281
Chain A, CruzipainTrypanosoma cruziPotency44.69030.002014.677939.8107AID1476; AID1478; AID2158
LuciferasePhotinus pyralis (common eastern firefly)Potency33.26110.007215.758889.3584AID1224835
interleukin 8Homo sapiens (human)Potency74.97800.047349.480674.9780AID651758
endonuclease IVEscherichia coliPotency5.62340.707912.432431.6228AID1708
acetylcholinesteraseHomo sapiens (human)Potency15.48710.002541.796015,848.9004AID1347398
thioredoxin reductaseRattus norvegicus (Norway rat)Potency30.40560.100020.879379.4328AID488772; AID488773; AID588453; AID588456
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency36.28913.189029.884159.4836AID1224846; AID1224894
RAR-related orphan receptor gammaMus musculus (house mouse)Potency50.11630.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency24.53060.173734.304761.8120AID1346859; AID1347035
ATAD5 protein, partialHomo sapiens (human)Potency22.44840.004110.890331.5287AID493106; AID493107; AID504467
Fumarate hydrataseHomo sapiens (human)Potency35.48130.00308.794948.0869AID1347053
NFKB1 protein, partialHomo sapiens (human)Potency0.22390.02827.055915.8489AID895; AID928
SMAD family member 3Homo sapiens (human)Potency24.53060.173734.304761.8120AID1346859; AID1347035
TDP1 proteinHomo sapiens (human)Potency13.37540.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency32.09290.000714.592883.7951AID1259368; AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency36.89240.000221.22318,912.5098AID1259243; AID1259247; AID1259381; AID588515; AID588516; AID743035; AID743036; AID743040; AID743042; AID743053; AID743054; AID743063
Smad3Homo sapiens (human)Potency14.12540.00527.809829.0929AID588855
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency68.97360.013326.981070.7614AID1346978
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency14.85730.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency33.14430.00137.762544.6684AID2120; AID914; AID915
thyroid stimulating hormone receptorHomo sapiens (human)Potency8.43480.001318.074339.8107AID926; AID938
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency28.92720.000657.913322,387.1992AID1259377; AID1259378; AID1259394
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency36.66600.001022.650876.6163AID1224839
progesterone receptorHomo sapiens (human)Potency25.91500.000417.946075.1148AID1346784; AID1347036
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency6.30960.28189.721235.4813AID2326
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency35.07570.000214.376460.0339AID588532; AID588533; AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency22.87780.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency21.27990.000817.505159.3239AID1159527; AID1159531; AID588544; AID588546
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency35.59850.001530.607315,848.9004AID1224819; AID1224820; AID1224821; AID1224823; AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency38.19320.375827.485161.6524AID588526; AID588527; AID743217; AID743220; AID743239
pregnane X nuclear receptorHomo sapiens (human)Potency39.80560.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency31.10990.000229.305416,493.5996AID1259244; AID1259248; AID588513; AID588514; AID743069; AID743075; AID743077; AID743078; AID743079; AID743080; AID743091
cytochrome P450 2D6Homo sapiens (human)Potency38.90180.00108.379861.1304AID1645840
polyproteinZika virusPotency35.48130.00308.794948.0869AID1347053
67.9K proteinVaccinia virusPotency17.12010.00018.4406100.0000AID720579; AID720580
glucocerebrosidaseHomo sapiens (human)Potency25.23480.01268.156944.6684AID2101
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency27.33200.001024.504861.6448AID588534; AID588535; AID743212; AID743215; AID743227
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency27.73910.001019.414170.9645AID588536; AID588537; AID743094; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency33.38980.023723.228263.5986AID588541; AID588543; AID743222; AID743223; AID743241
arylsulfatase AHomo sapiens (human)Potency0.10691.069113.955137.9330AID720538
alpha-galactosidaseHomo sapiens (human)Potency30.17634.466818.391635.4813AID1467; AID2107; AID957; AID992; AID998
pyruvate kinaseLeishmania mexicana mexicanaPotency15.84890.398113.744731.6228AID945; AID959
caspase-3Homo sapiens (human)Potency68.97360.013326.981070.7614AID1346978
IDH1Homo sapiens (human)Potency2.31090.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency7.94330.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency18.94990.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency4.17040.001723.839378.1014AID743083
activating transcription factor 6Homo sapiens (human)Potency36.82050.143427.612159.8106AID1159516; AID1159519
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency36.568619.739145.978464.9432AID1159509; AID1159518
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency33.01730.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency44.90580.039147.5451146.8240AID1224845
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency32.47080.036619.637650.1187AID1466; AID2112; AID2242
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency30.131323.934123.934123.9341AID1967
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency12.58930.316212.443531.6228AID924
tumor necrosis factorHomo sapiens (human)Potency47.30790.375823.492842.1632AID651757
polyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)Potency8.91251.000012.232631.6228AID1452
cytochrome P450 2C9 precursorHomo sapiens (human)Potency25.11890.00636.904339.8107AID883
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency9.07690.001815.663839.8107AID894
chromobox protein homolog 1Homo sapiens (human)Potency0.00600.006026.168889.1251AID488953
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency29.52160.010039.53711,122.0200AID588545; AID588547
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency31.83260.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency43.36670.000323.4451159.6830AID743065; AID743067
histone deacetylase 9 isoform 3Homo sapiens (human)Potency25.19780.037617.082361.1927AID1259364; AID1259388
heat shock protein beta-1Homo sapiens (human)Potency35.34760.042027.378961.6448AID743210; AID743228
importin subunit beta-1 isoform 1Homo sapiens (human)Potency54.60005.804836.130665.1308AID540253; AID540263
mitogen-activated protein kinase 1Homo sapiens (human)Potency0.02510.039816.784239.8107AID995
nuclear factor NF-kappa-B p105 subunit isoform 1Homo sapiens (human)Potency42.23954.466824.832944.6684AID651749
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency16.48160.00378.618923.2809AID2668
snurportin-1Homo sapiens (human)Potency54.60005.804836.130665.1308AID540253; AID540263
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency32.63740.000627.21521,122.0200AID651741; AID720636; AID743202; AID743219
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency21.33130.425612.059128.1838AID504536
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency9.20005.804816.996225.9290AID540253
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency2.23870.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency2.23870.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency2.23870.15855.287912.5893AID540303
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency14.97630.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency16.87710.004611.374133.4983AID463097; AID624296; AID624297
survival motor neuron protein isoform dHomo sapiens (human)Potency6.30960.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency39.81070.031610.279239.8107AID884; AID885
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency12.58930.00419.962528.1838AID2675
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency35.48130.251215.843239.8107AID504327
caspase-1 isoform alpha precursorHomo sapiens (human)Potency16.98930.000311.448431.6228AID900
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency0.00220.00106.000935.4813AID943
lethal factor (plasmid)Bacillus anthracis str. A2012Potency15.06540.020010.786931.6228AID912
lamin isoform A-delta10Homo sapiens (human)Potency7.08500.891312.067628.1838AID1487
pyruvate kinase PKM isoform bHomo sapiens (human)Potency12.58932.511912.262825.1189AID954; AID958
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency27.30600.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency28.17440.002319.595674.0614AID651631; AID651743; AID720552
Integrin beta-3Homo sapiens (human)Potency12.58930.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency12.58930.316211.415731.6228AID924
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency39.81073.548118.039535.4813AID1466
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Potency39.81073.548118.039535.4813AID1466
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency27.30600.001551.739315,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency25.11890.00638.235039.8107AID883
Caspase-7Homo sapiens (human)Potency12.81273.981118.585631.6228AID889
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency11.90471.000010.475628.1838AID1457
GABA theta subunitRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency64.47170.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency41.54490.011912.222168.7989AID588378; AID651632
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.16940.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Janus kinase 2 (a protein tyrosine kinase)Homo sapiens (human)IC50 (µMol)4.61300.22304.23727.5320AID1699
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)134.00000.11007.190310.0000AID1443980; AID1473738
Cathepsin GHomo sapiens (human)IC50 (µMol)7.41300.01372.42247.4130AID625175
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)10.00000.00002.015110.0000AID625249
Cyclin-dependent kinase 4Homo sapiens (human)IC50 (µMol)210.00000.00060.570610.0000AID1795925
G1/S-specific cyclin-D1Homo sapiens (human)IC50 (µMol)210.00000.00060.54799.5000AID1795925
Caspase-1Homo sapiens (human)IC50 (µMol)3.66300.00201.70138.8000AID625174
Casein kinase I isoform alphaHomo sapiens (human)IC50 (µMol)36.80000.00102.249910.0000AID1801866
Casein kinase I isoform deltaHomo sapiens (human)IC50 (µMol)31.60000.00401.127210.0000AID1801867
Casein kinase I isoform epsilonHomo sapiens (human)IC50 (µMol)31.60000.00401.11509.5000AID1801867
Pteridine reductase 1Leishmania majorKi3.40000.03901.57184.0000AID444877
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Hsf1 proteinMus musculus (house mouse)EC50 (µMol)195.00000.160024.4900236.5000AID2382
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (377)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
proteolysisCathepsin GHomo sapiens (human)
angiotensin maturationCathepsin GHomo sapiens (human)
monocyte chemotaxisCathepsin GHomo sapiens (human)
protein phosphorylationCathepsin GHomo sapiens (human)
proteolysisCathepsin GHomo sapiens (human)
immune responseCathepsin GHomo sapiens (human)
protein processingCathepsin GHomo sapiens (human)
cytokine-mediated signaling pathwayCathepsin GHomo sapiens (human)
protein metabolic processCathepsin GHomo sapiens (human)
antibacterial humoral responseCathepsin GHomo sapiens (human)
extracellular matrix disassemblyCathepsin GHomo sapiens (human)
platelet activationCathepsin GHomo sapiens (human)
purinergic nucleotide receptor signaling pathwayCathepsin GHomo sapiens (human)
neutrophil activationCathepsin GHomo sapiens (human)
positive regulation of immune responseCathepsin GHomo sapiens (human)
defense response to Gram-negative bacteriumCathepsin GHomo sapiens (human)
defense response to Gram-positive bacteriumCathepsin GHomo sapiens (human)
defense response to fungusCathepsin GHomo sapiens (human)
negative regulation of T cell activationCathepsin GHomo sapiens (human)
neutrophil-mediated killing of gram-positive bacteriumCathepsin GHomo sapiens (human)
cellular response to lipopolysaccharideCathepsin GHomo sapiens (human)
biofilm matrix disassemblyCathepsin GHomo sapiens (human)
positive regulation of platelet aggregationCathepsin GHomo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
G1/S transition of mitotic cell cycleCyclin-dependent kinase 4Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 4Homo sapiens (human)
positive regulation of cell population proliferationCyclin-dependent kinase 4Homo sapiens (human)
response to xenobiotic stimulusCyclin-dependent kinase 4Homo sapiens (human)
regulation of gene expressionCyclin-dependent kinase 4Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleCyclin-dependent kinase 4Homo sapiens (human)
positive regulation of fibroblast proliferationCyclin-dependent kinase 4Homo sapiens (human)
cell divisionCyclin-dependent kinase 4Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 4Homo sapiens (human)
regulation of transcription initiation by RNA polymerase IICyclin-dependent kinase 4Homo sapiens (human)
regulation of type B pancreatic cell proliferationCyclin-dependent kinase 4Homo sapiens (human)
cellular response to lipopolysaccharideCyclin-dependent kinase 4Homo sapiens (human)
cellular response to interleukin-4Cyclin-dependent kinase 4Homo sapiens (human)
cellular response to phorbol 13-acetate 12-myristateCyclin-dependent kinase 4Homo sapiens (human)
cellular response to ionomycinCyclin-dependent kinase 4Homo sapiens (human)
response to organic substanceCyclin-dependent kinase 4Homo sapiens (human)
regulation of G2/M transition of mitotic cell cycleCyclin-dependent kinase 4Homo sapiens (human)
signal transductionCyclin-dependent kinase 4Homo sapiens (human)
G1/S transition of mitotic cell cycleG1/S-specific cyclin-D1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIG1/S-specific cyclin-D1Homo sapiens (human)
re-entry into mitotic cell cycleG1/S-specific cyclin-D1Homo sapiens (human)
positive regulation of protein phosphorylationG1/S-specific cyclin-D1Homo sapiens (human)
DNA damage responseG1/S-specific cyclin-D1Homo sapiens (human)
lactationG1/S-specific cyclin-D1Homo sapiens (human)
response to xenobiotic stimulusG1/S-specific cyclin-D1Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleG1/S-specific cyclin-D1Homo sapiens (human)
Wnt signaling pathwayG1/S-specific cyclin-D1Homo sapiens (human)
neuron differentiationG1/S-specific cyclin-D1Homo sapiens (human)
negative regulation of epithelial cell differentiationG1/S-specific cyclin-D1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseG1/S-specific cyclin-D1Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingG1/S-specific cyclin-D1Homo sapiens (human)
mammary gland epithelial cell proliferationG1/S-specific cyclin-D1Homo sapiens (human)
positive regulation of mammary gland epithelial cell proliferationG1/S-specific cyclin-D1Homo sapiens (human)
negative regulation of neuron apoptotic processG1/S-specific cyclin-D1Homo sapiens (human)
response to leptinG1/S-specific cyclin-D1Homo sapiens (human)
fat cell differentiationG1/S-specific cyclin-D1Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityG1/S-specific cyclin-D1Homo sapiens (human)
cell divisionG1/S-specific cyclin-D1Homo sapiens (human)
mammary gland alveolus developmentG1/S-specific cyclin-D1Homo sapiens (human)
response to UV-AG1/S-specific cyclin-D1Homo sapiens (human)
liver regenerationG1/S-specific cyclin-D1Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleG1/S-specific cyclin-D1Homo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activityG1/S-specific cyclin-D1Homo sapiens (human)
cellular response to organic substanceCaspase-1Homo sapiens (human)
pattern recognition receptor signaling pathwayCaspase-1Homo sapiens (human)
proteolysisCaspase-1Homo sapiens (human)
apoptotic processCaspase-1Homo sapiens (human)
signal transductionCaspase-1Homo sapiens (human)
osmosensory signaling pathwayCaspase-1Homo sapiens (human)
protein autoprocessingCaspase-1Homo sapiens (human)
positive regulation of interleukin-1 beta productionCaspase-1Homo sapiens (human)
positive regulation of interleukin-18 productionCaspase-1Homo sapiens (human)
defense response to bacteriumCaspase-1Homo sapiens (human)
regulation of apoptotic processCaspase-1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionCaspase-1Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processCaspase-1Homo sapiens (human)
icosanoid biosynthetic processCaspase-1Homo sapiens (human)
regulation of inflammatory responseCaspase-1Homo sapiens (human)
positive regulation of inflammatory responseCaspase-1Homo sapiens (human)
protein maturationCaspase-1Homo sapiens (human)
defense response to virusCaspase-1Homo sapiens (human)
pyroptosisCaspase-1Homo sapiens (human)
cellular response to lipopolysaccharideCaspase-1Homo sapiens (human)
cellular response to mechanical stimulusCaspase-1Homo sapiens (human)
cellular response to type II interferonCaspase-1Homo sapiens (human)
cytokine precursor processingCaspase-1Homo sapiens (human)
signaling receptor ligand precursor processingCaspase-1Homo sapiens (human)
AIM2 inflammasome complex assemblyCaspase-1Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayCaspase-1Homo sapiens (human)
protein phosphorylationCasein kinase I isoform alphaHomo sapiens (human)
Golgi organizationCasein kinase I isoform alphaHomo sapiens (human)
cell surface receptor signaling pathwayCasein kinase I isoform alphaHomo sapiens (human)
Wnt signaling pathwayCasein kinase I isoform alphaHomo sapiens (human)
peptidyl-serine phosphorylationCasein kinase I isoform alphaHomo sapiens (human)
viral protein processingCasein kinase I isoform alphaHomo sapiens (human)
cellular response to nutrientCasein kinase I isoform alphaHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase I isoform alphaHomo sapiens (human)
positive regulation of Rho protein signal transductionCasein kinase I isoform alphaHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processCasein kinase I isoform alphaHomo sapiens (human)
intermediate filament cytoskeleton organizationCasein kinase I isoform alphaHomo sapiens (human)
cell divisionCasein kinase I isoform alphaHomo sapiens (human)
negative regulation of canonical Wnt signaling pathwayCasein kinase I isoform alphaHomo sapiens (human)
negative regulation of NLRP3 inflammasome complex assemblyCasein kinase I isoform alphaHomo sapiens (human)
positive regulation of TORC1 signalingCasein kinase I isoform alphaHomo sapiens (human)
signal transductionCasein kinase I isoform alphaHomo sapiens (human)
microtubule nucleationCasein kinase I isoform deltaHomo sapiens (human)
Golgi organizationCasein kinase I isoform deltaHomo sapiens (human)
protein localization to Golgi apparatusCasein kinase I isoform deltaHomo sapiens (human)
protein localization to ciliumCasein kinase I isoform deltaHomo sapiens (human)
protein localization to centrosomeCasein kinase I isoform deltaHomo sapiens (human)
non-motile cilium assemblyCasein kinase I isoform deltaHomo sapiens (human)
positive regulation of protein phosphorylationCasein kinase I isoform deltaHomo sapiens (human)
protein phosphorylationCasein kinase I isoform deltaHomo sapiens (human)
Wnt signaling pathwayCasein kinase I isoform deltaHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase I isoform deltaHomo sapiens (human)
circadian regulation of gene expressionCasein kinase I isoform deltaHomo sapiens (human)
regulation of circadian rhythmCasein kinase I isoform deltaHomo sapiens (human)
COPII vesicle coatingCasein kinase I isoform deltaHomo sapiens (human)
spindle assemblyCasein kinase I isoform deltaHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayCasein kinase I isoform deltaHomo sapiens (human)
midbrain dopaminergic neuron differentiationCasein kinase I isoform deltaHomo sapiens (human)
cellular response to nerve growth factor stimulusCasein kinase I isoform deltaHomo sapiens (human)
positive regulation of non-canonical Wnt signaling pathwayCasein kinase I isoform deltaHomo sapiens (human)
peptidyl-serine phosphorylationCasein kinase I isoform deltaHomo sapiens (human)
signal transductionCasein kinase I isoform deltaHomo sapiens (human)
non-motile cilium assemblyCasein kinase I isoform deltaHomo sapiens (human)
endocytosisCasein kinase I isoform deltaHomo sapiens (human)
DNA repairCasein kinase I isoform epsilonHomo sapiens (human)
protein phosphorylationCasein kinase I isoform epsilonHomo sapiens (human)
protein localizationCasein kinase I isoform epsilonHomo sapiens (human)
negative regulation of Wnt signaling pathwayCasein kinase I isoform epsilonHomo sapiens (human)
negative regulation of protein bindingCasein kinase I isoform epsilonHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase I isoform epsilonHomo sapiens (human)
regulation of protein localizationCasein kinase I isoform epsilonHomo sapiens (human)
circadian regulation of gene expressionCasein kinase I isoform epsilonHomo sapiens (human)
regulation of circadian rhythmCasein kinase I isoform epsilonHomo sapiens (human)
circadian behaviorCasein kinase I isoform epsilonHomo sapiens (human)
canonical Wnt signaling pathwayCasein kinase I isoform epsilonHomo sapiens (human)
positive regulation of amyloid-beta formationCasein kinase I isoform epsilonHomo sapiens (human)
cellular response to nerve growth factor stimulusCasein kinase I isoform epsilonHomo sapiens (human)
positive regulation of non-canonical Wnt signaling pathwayCasein kinase I isoform epsilonHomo sapiens (human)
peptidyl-serine phosphorylationCasein kinase I isoform epsilonHomo sapiens (human)
endocytosisCasein kinase I isoform epsilonHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayCasein kinase I isoform epsilonHomo sapiens (human)
signal transductionCasein kinase I isoform epsilonHomo sapiens (human)
proteolysisCaspase-7Homo sapiens (human)
apoptotic processCaspase-7Homo sapiens (human)
heart developmentCaspase-7Homo sapiens (human)
response to UVCaspase-7Homo sapiens (human)
protein processingCaspase-7Homo sapiens (human)
protein catabolic processCaspase-7Homo sapiens (human)
defense response to bacteriumCaspase-7Homo sapiens (human)
fibroblast apoptotic processCaspase-7Homo sapiens (human)
striated muscle cell differentiationCaspase-7Homo sapiens (human)
neuron apoptotic processCaspase-7Homo sapiens (human)
protein maturationCaspase-7Homo sapiens (human)
lymphocyte apoptotic processCaspase-7Homo sapiens (human)
cellular response to lipopolysaccharideCaspase-7Homo sapiens (human)
cellular response to staurosporineCaspase-7Homo sapiens (human)
execution phase of apoptosisCaspase-7Homo sapiens (human)
positive regulation of plasma membrane repairCaspase-7Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-7Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (114)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
serine-type endopeptidase activityCathepsin GHomo sapiens (human)
protein bindingCathepsin GHomo sapiens (human)
heparin bindingCathepsin GHomo sapiens (human)
peptidase activityCathepsin GHomo sapiens (human)
serine-type peptidase activityCathepsin GHomo sapiens (human)
receptor ligand activityCathepsin GHomo sapiens (human)
caspase bindingCathepsin GHomo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 4Homo sapiens (human)
protein bindingCyclin-dependent kinase 4Homo sapiens (human)
ATP bindingCyclin-dependent kinase 4Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase regulator activityCyclin-dependent kinase 4Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 4Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 4Homo sapiens (human)
transcription corepressor activityG1/S-specific cyclin-D1Homo sapiens (human)
protein kinase activityG1/S-specific cyclin-D1Homo sapiens (human)
protein bindingG1/S-specific cyclin-D1Homo sapiens (human)
enzyme bindingG1/S-specific cyclin-D1Homo sapiens (human)
protein kinase bindingG1/S-specific cyclin-D1Homo sapiens (human)
histone deacetylase bindingG1/S-specific cyclin-D1Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activator activityG1/S-specific cyclin-D1Homo sapiens (human)
proline-rich region bindingG1/S-specific cyclin-D1Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase regulator activityG1/S-specific cyclin-D1Homo sapiens (human)
endopeptidase activityCaspase-1Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-1Homo sapiens (human)
protein bindingCaspase-1Homo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processCaspase-1Homo sapiens (human)
kinase bindingCaspase-1Homo sapiens (human)
cytokine bindingCaspase-1Homo sapiens (human)
identical protein bindingCaspase-1Homo sapiens (human)
CARD domain bindingCaspase-1Homo sapiens (human)
caspase bindingCaspase-1Homo sapiens (human)
protein kinase activityCasein kinase I isoform alphaHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase I isoform alphaHomo sapiens (human)
protein bindingCasein kinase I isoform alphaHomo sapiens (human)
ATP bindingCasein kinase I isoform alphaHomo sapiens (human)
protein serine kinase activityCasein kinase I isoform alphaHomo sapiens (human)
protein kinase activityCasein kinase I isoform deltaHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase I isoform deltaHomo sapiens (human)
protein bindingCasein kinase I isoform deltaHomo sapiens (human)
ATP bindingCasein kinase I isoform deltaHomo sapiens (human)
cadherin bindingCasein kinase I isoform deltaHomo sapiens (human)
tau-protein kinase activityCasein kinase I isoform deltaHomo sapiens (human)
protein serine kinase activityCasein kinase I isoform deltaHomo sapiens (human)
RNA bindingCasein kinase I isoform epsilonHomo sapiens (human)
protein kinase activityCasein kinase I isoform epsilonHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase I isoform epsilonHomo sapiens (human)
protein bindingCasein kinase I isoform epsilonHomo sapiens (human)
ATP bindingCasein kinase I isoform epsilonHomo sapiens (human)
protein serine kinase activityCasein kinase I isoform epsilonHomo sapiens (human)
RNA bindingCaspase-7Homo sapiens (human)
aspartic-type endopeptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-7Homo sapiens (human)
protein bindingCaspase-7Homo sapiens (human)
peptidase activityCaspase-7Homo sapiens (human)
cysteine-type peptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in execution phase of apoptosisCaspase-7Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (97)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
collagen-containing extracellular matrixCathepsin GHomo sapiens (human)
extracellular regionCathepsin GHomo sapiens (human)
extracellular spaceCathepsin GHomo sapiens (human)
nucleusCathepsin GHomo sapiens (human)
lysosomeCathepsin GHomo sapiens (human)
cytosolCathepsin GHomo sapiens (human)
plasma membraneCathepsin GHomo sapiens (human)
cytoplasmic stress granuleCathepsin GHomo sapiens (human)
membraneCathepsin GHomo sapiens (human)
secretory granuleCathepsin GHomo sapiens (human)
azurophil granule lumenCathepsin GHomo sapiens (human)
collagen-containing extracellular matrixCathepsin GHomo sapiens (human)
extracellular exosomeCathepsin GHomo sapiens (human)
cytoplasmCathepsin GHomo sapiens (human)
intracellular membrane-bounded organelleCathepsin GHomo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
nucleusCyclin-dependent kinase 4Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 4Homo sapiens (human)
nucleolusCyclin-dependent kinase 4Homo sapiens (human)
cytosolCyclin-dependent kinase 4Homo sapiens (human)
bicellular tight junctionCyclin-dependent kinase 4Homo sapiens (human)
nuclear membraneCyclin-dependent kinase 4Homo sapiens (human)
cyclin D1-CDK4 complexCyclin-dependent kinase 4Homo sapiens (human)
cyclin D2-CDK4 complexCyclin-dependent kinase 4Homo sapiens (human)
cyclin D3-CDK4 complexCyclin-dependent kinase 4Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 4Homo sapiens (human)
chromatinCyclin-dependent kinase 4Homo sapiens (human)
transcription regulator complexCyclin-dependent kinase 4Homo sapiens (human)
nucleusCyclin-dependent kinase 4Homo sapiens (human)
cytoplasmCyclin-dependent kinase 4Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
nucleusG1/S-specific cyclin-D1Homo sapiens (human)
nucleoplasmG1/S-specific cyclin-D1Homo sapiens (human)
cytosolG1/S-specific cyclin-D1Homo sapiens (human)
bicellular tight junctionG1/S-specific cyclin-D1Homo sapiens (human)
nuclear membraneG1/S-specific cyclin-D1Homo sapiens (human)
cyclin D1-CDK4 complexG1/S-specific cyclin-D1Homo sapiens (human)
cyclin D1-CDK6 complexG1/S-specific cyclin-D1Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexG1/S-specific cyclin-D1Homo sapiens (human)
transcription repressor complexG1/S-specific cyclin-D1Homo sapiens (human)
centrosomeG1/S-specific cyclin-D1Homo sapiens (human)
cytoplasmG1/S-specific cyclin-D1Homo sapiens (human)
nucleusG1/S-specific cyclin-D1Homo sapiens (human)
cytoplasmCaspase-1Homo sapiens (human)
cytosolCaspase-1Homo sapiens (human)
nucleolusCaspase-1Homo sapiens (human)
cytoplasmCaspase-1Homo sapiens (human)
cytosolCaspase-1Homo sapiens (human)
microtubuleCaspase-1Homo sapiens (human)
plasma membraneCaspase-1Homo sapiens (human)
canonical inflammasome complexCaspase-1Homo sapiens (human)
NLRP1 inflammasome complexCaspase-1Homo sapiens (human)
NLRP3 inflammasome complexCaspase-1Homo sapiens (human)
AIM2 inflammasome complexCaspase-1Homo sapiens (human)
protein-containing complexCaspase-1Homo sapiens (human)
IPAF inflammasome complexCaspase-1Homo sapiens (human)
protease inhibitor complexCaspase-1Homo sapiens (human)
mRNA cleavage and polyadenylation specificity factor complexCasein kinase I isoform alphaHomo sapiens (human)
keratin filamentCasein kinase I isoform alphaHomo sapiens (human)
kinetochoreCasein kinase I isoform alphaHomo sapiens (human)
centrosomeCasein kinase I isoform alphaHomo sapiens (human)
spindleCasein kinase I isoform alphaHomo sapiens (human)
cytosolCasein kinase I isoform alphaHomo sapiens (human)
ciliumCasein kinase I isoform alphaHomo sapiens (human)
membraneCasein kinase I isoform alphaHomo sapiens (human)
nuclear speckCasein kinase I isoform alphaHomo sapiens (human)
beta-catenin destruction complexCasein kinase I isoform alphaHomo sapiens (human)
ciliary basal bodyCasein kinase I isoform alphaHomo sapiens (human)
cytoplasmCasein kinase I isoform alphaHomo sapiens (human)
nucleusCasein kinase I isoform alphaHomo sapiens (human)
nucleusCasein kinase I isoform deltaHomo sapiens (human)
nucleoplasmCasein kinase I isoform deltaHomo sapiens (human)
Golgi apparatusCasein kinase I isoform deltaHomo sapiens (human)
centrosomeCasein kinase I isoform deltaHomo sapiens (human)
spindleCasein kinase I isoform deltaHomo sapiens (human)
cytosolCasein kinase I isoform deltaHomo sapiens (human)
spindle microtubuleCasein kinase I isoform deltaHomo sapiens (human)
plasma membraneCasein kinase I isoform deltaHomo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartment membraneCasein kinase I isoform deltaHomo sapiens (human)
ciliary basal bodyCasein kinase I isoform deltaHomo sapiens (human)
perinuclear region of cytoplasmCasein kinase I isoform deltaHomo sapiens (human)
nucleusCasein kinase I isoform deltaHomo sapiens (human)
cytoplasmCasein kinase I isoform deltaHomo sapiens (human)
spindle microtubuleCasein kinase I isoform deltaHomo sapiens (human)
nucleusCasein kinase I isoform epsilonHomo sapiens (human)
nucleoplasmCasein kinase I isoform epsilonHomo sapiens (human)
cytoplasmCasein kinase I isoform epsilonHomo sapiens (human)
cytosolCasein kinase I isoform epsilonHomo sapiens (human)
growth coneCasein kinase I isoform epsilonHomo sapiens (human)
neuronal cell bodyCasein kinase I isoform epsilonHomo sapiens (human)
ribonucleoprotein complexCasein kinase I isoform epsilonHomo sapiens (human)
cytoplasmCasein kinase I isoform epsilonHomo sapiens (human)
nucleusCasein kinase I isoform epsilonHomo sapiens (human)
extracellular spaceCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
cytoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
nucleoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (306)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID524774Antiplasmodial activity against Plasmodium falciparum GB4 harboring polymorphic DHFR after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID232830Volume of urine 1 hr after the compound was administered 125 mg/kg po in rat1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID524805Antiplasmodial activity against Plasmodium falciparum KH7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1149702Diuretic activity in saline-loaded Wistar albino rat assessed as increase of saline-load excretion at 15 mg/kg, ip measured for 6 hrs relative to control1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
2,3-Disubstituted 1,8-naphthyridines as potential diuretic agents. 2. 5,7-Dimethyl derivatives.
AID624628Drug-stimulated Pgp ATPase activity ratio determined in MDR1-Sf9 cell membranes with test compound at a concentration of 20uM2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID524799Antiplasmodial activity against Plasmodium falciparum XD8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID21822Mean urinary output in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID16938Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
1-(2-aminoethyl)-6-aryl-4H- [1,2,4]triazolo[4,3-a][1,4]benzodiazepines with diuretic and natriuretic activity.
AID624623Apparent permeability (Papp) from basolateral to apical side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID190622Post dosing time interval of maximum activity1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID21802Mean urinary output in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID230248Ratio of Na+ to K+ excretion at dose1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID524807Antiplasmodial activity against Plasmodium falciparum JB12 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524768Antiplasmodial activity against Plasmodium falciparum WE2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID15928Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID16933Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
1-(2-aminoethyl)-6-aryl-4H- [1,2,4]triazolo[4,3-a][1,4]benzodiazepines with diuretic and natriuretic activity.
AID17301Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID316226Inhibition of PAK1 at 31 uM2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Kinase-likeness and kinase-privileged fragments: toward virtual polypharmacology.
AID19878Mean excretion of sodium in conscious rats at a dose of 30 mg/kg given orally1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
1-(2-aminoethyl)-6-aryl-4H- [1,2,4]triazolo[4,3-a][1,4]benzodiazepines with diuretic and natriuretic activity.
AID524820Antiplasmodial activity against Plasmodium falciparum JB8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID521885Antiplasmodial activity against transgenic Plasmodium falciparum Dd2 pDT harboring polymorphic DHFR after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID197598Lysozyme-conjugated prodrugs: in vitro stability at pH 7.41992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates.
AID17297Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID21810Mean urinary output in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID16859Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID524806Antiplasmodial activity against Plasmodium falciparum NIC after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID521892Selectivity ratio of IC50 for Plasmodium falciparum 7G8 to IC50 for Plasmodium falciparum GB42009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID21806Mean urinary output in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID524804Antiplasmodial activity against Plasmodium falciparum TF1 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID17313Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID524821Antiplasmodial activity against Plasmodium falciparum WC4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID19868Mean excretion of potassium in conscious rats at a dose of 1.0 mg/kg given orally1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
1-(2-aminoethyl)-6-aryl-4H- [1,2,4]triazolo[4,3-a][1,4]benzodiazepines with diuretic and natriuretic activity.
AID232831Volume of urine 2 hr after the compound was administered 125 mg/kg po in rat1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID16689Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID129601Acute toxicity in mice when given po1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524767Antiplasmodial activity against Plasmodium falciparum KC2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID232826Urinary sodium 2 hr after the compound was administered 125 mg/kg po in rat1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID19867Mean excretion of potassium in conscious rats at a dose of 0.3 mg/kg given orally1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
1-(2-aminoethyl)-6-aryl-4H- [1,2,4]triazolo[4,3-a][1,4]benzodiazepines with diuretic and natriuretic activity.
AID19874Mean excretion of sodium in conscious rats at a dose of 1.0 mg/kg given orally1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
1-(2-aminoethyl)-6-aryl-4H- [1,2,4]triazolo[4,3-a][1,4]benzodiazepines with diuretic and natriuretic activity.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID19869Mean excretion of potassium in conscious rats at a dose of 10 mg/kg given orally1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
1-(2-aminoethyl)-6-aryl-4H- [1,2,4]triazolo[4,3-a][1,4]benzodiazepines with diuretic and natriuretic activity.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524798Antiplasmodial activity against Plasmodium falciparum KC5 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID16937Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
1-(2-aminoethyl)-6-aryl-4H- [1,2,4]triazolo[4,3-a][1,4]benzodiazepines with diuretic and natriuretic activity.
AID524800Antiplasmodial activity against Plasmodium falciparum XB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID16931Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
1-(2-aminoethyl)-6-aryl-4H- [1,2,4]triazolo[4,3-a][1,4]benzodiazepines with diuretic and natriuretic activity.
AID524808Antiplasmodial activity against Plasmodium falciparum D2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524814Antiplasmodial activity against Plasmodium falciparum JON after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524815Antiplasmodial activity against Plasmodium falciparum NF10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID624626Ratio of apparent permeability from basolateral to apical side over apical to basolateral side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID197600Lysozyme-conjugated prodrugs: in vitro stability in rat cortical homogenate at pH 51992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID524797Antiplasmodial activity against Plasmodium falciparum KB8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID16063Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID16851Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID19870Mean excretion of potassium in conscious rats at a dose of 100 mg/kg given orally1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
1-(2-aminoethyl)-6-aryl-4H- [1,2,4]triazolo[4,3-a][1,4]benzodiazepines with diuretic and natriuretic activity.
AID1149701Diuretic activity in saline-loaded Wistar albino rat assessed as increase of saline-load excretion at 2 mg/kg, ip measured for 6 hrs relative to control1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
2,3-Disubstituted 1,8-naphthyridines as potential diuretic agents. 2. 5,7-Dimethyl derivatives.
AID52790Inhibition of chymotrypsin at 250 uM2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID17305Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444878Inhibition of Trypanosoma brucei recombinant PTR12010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Structure-based design of pteridine reductase inhibitors targeting African sleeping sickness and the leishmaniases.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID21826Mean urinary output in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID521890Antiplasmodial activity against Plasmodium falciparum D10 harboring polymorphic DHFR after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID521888Antiplasmodial activity against Plasmodium falciparum W2 harboring polymorphic DHFR after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID17309Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID197602Lysozyme-conjugated prodrugs: in vitro stability in rat cortical homogenate at pH 7.41992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates.
AID19872Mean excretion of potassium in conscious rats at a dose of 30 mg/kg given orally1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
1-(2-aminoethyl)-6-aryl-4H- [1,2,4]triazolo[4,3-a][1,4]benzodiazepines with diuretic and natriuretic activity.
AID524765Antiplasmodial activity against Plasmodium falciparum JF11 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID173967Dose required to produce increase in 200 % in urine production vs control groups;Not determined1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID232833Volume of urine 4 hr after the compound was administered 125 mg/kg po in rat1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID16071Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID19877Mean excretion of sodium in conscious rats at a dose of 3.0 mg/kg given orally1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
1-(2-aminoethyl)-6-aryl-4H- [1,2,4]triazolo[4,3-a][1,4]benzodiazepines with diuretic and natriuretic activity.
AID524801Antiplasmodial activity against Plasmodium falciparum JC9 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524809Antiplasmodial activity against Plasmodium falciparum XE7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID21778Mean urinary output in rats (Control/Drug treatment value); Value 23.9/37.21992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID19861Mean excretion of chloride in conscious rats at a dose of 1.0 mg/kg given orally1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
1-(2-aminoethyl)-6-aryl-4H- [1,2,4]triazolo[4,3-a][1,4]benzodiazepines with diuretic and natriuretic activity.
AID444877Inhibition of Leishmania major recombinant PTR12010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Structure-based design of pteridine reductase inhibitors targeting African sleeping sickness and the leishmaniases.
AID524810Antiplasmodial activity against Plasmodium falciparum LC12 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID624622Apparent permeability (Papp) from apical to basolateral side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID524773Antiplasmodial activity against Plasmodium falciparum DEV after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID197596Lysozyme-conjugated prodrugs: in vitro stability at pH 51992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates.
AID17123Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.321992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID524803Antiplasmodial activity against Plasmodium falciparum AL2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1149705Natriuretic activity in nonloaded rat assessed as increase in Na+ secretion at 15 mg/kg after 6 hrs relative to control1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
2,3-Disubstituted 1,8-naphthyridines as potential diuretic agents. 2. 5,7-Dimethyl derivatives.
AID176936Dose required to produce increase in 50 % in urine production vs control groups1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID16697Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID524802Antiplasmodial activity against Plasmodium falciparum AUD after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID19876Mean excretion of sodium in conscious rats at a dose of 100 mg/kg given orally1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
1-(2-aminoethyl)-6-aryl-4H- [1,2,4]triazolo[4,3-a][1,4]benzodiazepines with diuretic and natriuretic activity.
AID21814Mean urinary output in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID220180Inhibitory activity against CDK4 using recombinant human cyclin D2-CDK4 complex expressed in sf9 cells2001Journal of medicinal chemistry, Dec-20, Volume: 44, Issue:26
Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design.
AID524816Antiplasmodial activity against Plasmodium falciparum QF5 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID19866Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
1-(2-aminoethyl)-6-aryl-4H- [1,2,4]triazolo[4,3-a][1,4]benzodiazepines with diuretic and natriuretic activity.
AID624629Inhibition of Pgp expressed in MDR1-MDCKII cells measured by calcein-AM assay2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID521889Antiplasmodial activity against Plasmodium falciparum 7G8 harboring polymorphic DHFR after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID16075Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID19871Mean excretion of potassium in conscious rats at a dose of 3.0 mg/kg given orally1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
1-(2-aminoethyl)-6-aryl-4H- [1,2,4]triazolo[4,3-a][1,4]benzodiazepines with diuretic and natriuretic activity.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID16083Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID316227Inhibition of p70S6K at 33 uM2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Kinase-likeness and kinase-privileged fragments: toward virtual polypharmacology.
AID16936Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
1-(2-aminoethyl)-6-aryl-4H- [1,2,4]triazolo[4,3-a][1,4]benzodiazepines with diuretic and natriuretic activity.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID16059Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID16079Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID1149709Diuretic activity in nonloaded rat assessed as urine volume at 15 mg/kg after 6 hrs relative to control1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
2,3-Disubstituted 1,8-naphthyridines as potential diuretic agents. 2. 5,7-Dimethyl derivatives.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID524817Antiplasmodial activity against Plasmodium falciparum WF12 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524811Antiplasmodial activity against Plasmodium falciparum JH6 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID521887Antiplasmodial activity against Plasmodium falciparum Dd2 harboring polymorphic DHFR after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID232825Urinary sodium 1 hr after the compound was administered 125 mg/kg po in rat1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID16847Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID524775Antiplasmodial activity against Plasmodium falciparum 3D7 harboring polymorphic DHFR after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID19863Mean excretion of chloride in conscious rats at a dose of 100 mg/kg given orally1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
1-(2-aminoethyl)-6-aryl-4H- [1,2,4]triazolo[4,3-a][1,4]benzodiazepines with diuretic and natriuretic activity.
AID524818Antiplasmodial activity against Plasmodium falciparum XF12 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID232828Urinary sodium 4 hr after the compound was administered 125 mg/kg po in rat1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID19424Partition coefficient (logD7.4)2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
AID26304Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID232834Volume of urine 6 hr after the compound was administered 125 mg/kg po in rat1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID316228Inhibition of SGK1 at 33 uM2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Kinase-likeness and kinase-privileged fragments: toward virtual polypharmacology.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID173776Dose required to produce an excretion of 2 mequiv of Na+/kg bw/6h vs control groups1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID232832Volume of urine 3h after the compound was administered 125 mg/kg po in rat1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID16067Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID16701Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID17317Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID524812Antiplasmodial activity against Plasmodium falciparum LA10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524813Antiplasmodial activity against Plasmodium falciparum KA6 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID19862Mean excretion of chloride in conscious rats at a dose of 10 mg/kg given orally1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
1-(2-aminoethyl)-6-aryl-4H- [1,2,4]triazolo[4,3-a][1,4]benzodiazepines with diuretic and natriuretic activity.
AID19875Mean excretion of sodium in conscious rats at a dose of 10 mg/kg given orally1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
1-(2-aminoethyl)-6-aryl-4H- [1,2,4]triazolo[4,3-a][1,4]benzodiazepines with diuretic and natriuretic activity.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID232827Urinary sodium 3h after the compound was administered 125 mg/kg po in rat1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID16693Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID19865Mean excretion of chloride in conscious rats at a dose of 3.0 mg/kg given orally1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
1-(2-aminoethyl)-6-aryl-4H- [1,2,4]triazolo[4,3-a][1,4]benzodiazepines with diuretic and natriuretic activity.
AID524766Antiplasmodial activity against Plasmodium falciparum XG10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID19873Mean excretion of sodium in conscious rats at a dose of 0.3 mg/kg given orally1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
1-(2-aminoethyl)-6-aryl-4H- [1,2,4]triazolo[4,3-a][1,4]benzodiazepines with diuretic and natriuretic activity.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID524819Antiplasmodial activity against Plasmodium falciparum DAN after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID521891Antiplasmodial activity against Plasmodium falciparum HB3 harboring polymorphic DHFR after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID16935Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
1-(2-aminoethyl)-6-aryl-4H- [1,2,4]triazolo[4,3-a][1,4]benzodiazepines with diuretic and natriuretic activity.
AID232829Urinary sodium 6 hr after the compound was administered 125 mg/kg po in rat1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID17293Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1149711Ratio of natriuretic activity in nonloaded rat assessed as increase in Na+ secretion at 15 mg/kg to kaliuretic activity in nonloaded rat assessed as increase in K+ secretion at 15 mg/kg1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
2,3-Disubstituted 1,8-naphthyridines as potential diuretic agents. 2. 5,7-Dimethyl derivatives.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID43581Inhibition of beta-lactamase at 100 uM2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID524763Antiplasmodial activity against Plasmodium falciparum JC3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID21818Mean urinary output in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID19864Mean excretion of chloride in conscious rats at a dose of 30 mg/kg given orally1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
1-(2-aminoethyl)-6-aryl-4H- [1,2,4]triazolo[4,3-a][1,4]benzodiazepines with diuretic and natriuretic activity.
AID21830Mean urinary output in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID17321Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID521886Antiplasmodial activity against transgenic Plasmodium falciparum HB3 pDT harboring polymorphic DHFR after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1149706Toxicity in nonloaded rat assessed as kaluretic effect by measuring increase in K+ secretion at 15 mg/kg after 6 hrs relative to control1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
2,3-Disubstituted 1,8-naphthyridines as potential diuretic agents. 2. 5,7-Dimethyl derivatives.
AID106807Compound was tested for the inhibition of malate dehydrogenase (MDH) at 50 uM2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID22293Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID16855Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
N-substituted pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. A new class of diuretics.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1801867KinaseGlou00AE Plus Luminescent Assay from Article 10.1016/j.chembiol.2016.02.015: \\Epiblastin A Induces Reprogramming of Epiblast Stem Cells Into Embryonic Stem Cells by Inhibition of Casein Kinase 1.\\2016Cell chemical biology, 04-21, Volume: 23, Issue:4
Epiblastin A Induces Reprogramming of Epiblast Stem Cells Into Embryonic Stem Cells by Inhibition of Casein Kinase 1.
AID1795925CDKs Assay from Article 10.1021/jm0103256: \\Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design.\\2001Journal of medicinal chemistry, Dec-20, Volume: 44, Issue:26
Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design.
AID1801866Radiometric-Based Assay (CK1α) from Article 10.1016/j.chembiol.2016.02.015: \\Epiblastin A Induces Reprogramming of Epiblast Stem Cells Into Embryonic Stem Cells by Inhibition of Casein Kinase 1.\\2016Cell chemical biology, 04-21, Volume: 23, Issue:4
Epiblastin A Induces Reprogramming of Epiblast Stem Cells Into Embryonic Stem Cells by Inhibition of Casein Kinase 1.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,137)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990854 (75.11)18.7374
1990's124 (10.91)18.2507
2000's59 (5.19)29.6817
2010's74 (6.51)24.3611
2020's26 (2.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 82.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index82.55 (24.57)
Research Supply Index7.24 (2.92)
Research Growth Index4.38 (4.65)
Search Engine Demand Index149.78 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (82.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials181 (14.93%)5.53%
Reviews67 (5.53%)6.00%
Case Studies119 (9.82%)4.05%
Observational1 (0.08%)0.25%
Other844 (69.64%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Crossover Pilot Study of the Effect of Amiloride on Proteinuria in Patients With Proteinuric Kidney Disease [NCT02522650]Phase 430 participants (Anticipated)Interventional2013-07-31Recruiting
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans [NCT04467931]22,213 participants (Actual)Observational2020-01-19Completed
[NCT00000525]Phase 3233 participants (Actual)Interventional1986-07-31Completed
Increased Activity of the Epithelial Sodium Channel (ENaC) in Diabetic Nephropathy [NCT01918488]80 participants (Anticipated)Interventional2013-10-31Enrolling by invitation
Action to Control Cardiovascular Risk in Diabetes (ACCORD) [NCT00000620]Phase 310,251 participants (Actual)Interventional1999-09-30Completed
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Amiloride vs Triamterene [NCT05125237]146,670 participants (Actual)Observational2021-10-01Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00000620 (6) [back to overview]Death From Any Cause in the Glycemia Trial.
NCT00000620 (6) [back to overview]First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.
NCT00000620 (6) [back to overview]First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.
NCT00000620 (6) [back to overview]First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.
NCT00000620 (6) [back to overview]First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.
NCT00000620 (6) [back to overview]Stroke in the Blood Pressure Trial.

Death From Any Cause in the Glycemia Trial.

"Time to death from any cause. Secondary measure for Glycemia Trial.~A finding of higher mortality in the intensive-therapy group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid)." (NCT00000620)
Timeframe: 4.9 years

Interventionparticipants (Number)
Glycemia Trial: Intensive Control391
Glycemia Trial: Standard Control327

[back to top]

First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.

"Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. This was the primary outcome measure in all three trials: Glycemia (all participants), Blood Pressure (subgroup of participants not in Lipid Trial), and Lipid (subgroup of participants not in Blood Pressure Trial).~In the Glycemia Trial, a finding of higher mortality in the intensive arm group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid) to their planned completion." (NCT00000620)
Timeframe: 4.9 years

Interventionparticipants (Number)
Glycemia Trial: Intensive Control503
Glycemia Trial: Standard Control543

[back to top]

First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.

Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Primary outcome for Blood Pressure Trial. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
BP Trial: Intensive Control208
BP Trial: Standard Control237

[back to top]

First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.

Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
Lipid Trial: Fenofibrate291
Lipid Trial: Placebo310

[back to top]

First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.

Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, revascularization procedure or hospitalization for CHF in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
Lipid Trial: Fenofibrate641
Lipid Trial: Placebo667

[back to top]

Stroke in the Blood Pressure Trial.

Time to first occurrence of nonfatal or fatal stroke among participants in the BP Trial. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
BP Trial: Intensive Control36
BP Trial: Standard Control62

[back to top]